- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
Article
FDA approves Stelara for treatment of psoriasis
Author(s):
Horsham, Pa. ? The U.S. Food and Drug Administration (FDA) has approved the biologic Stelara (ustekinumab, Centocor Ortho Biotech) for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy, according to a Centocor press release.
Horsham, Pa.
- The U.S. Food and Drug Administration (FDA) has approved the biologic Stelara (ustekinumab, Centocor Ortho Biotech) for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy, according to a Centocor press release.
Stelara is a human monoclonal antibody that targets cytokines interleukin-12 (IL-12) and interleukin-23 (IL-23), proteins believed to be associated with the development of psoriasis.
The clinical development program for Stelara included more than 2,200 patients and two pivotal phase 3 trials. In each of the trials, a significantly higher proportion of patients receiving either 45 mg or 90 mg of Stelara achieved at least a 75 percent reduction in psoriasis, measured by the Psoriasis Area and Severity Index (PASI), at week 12 as compared to placebo, according to Centocor.
The drug is administered as a subcutaneous injection given at weeks zero and four, followed by a dosing every 12 weeks.
